Fundraising Fox

Gesynta Pharma

Stockholm, SE · 7 known investors

Find your way into Gesynta Pharma

143 people in our graph share verified history with the Gesynta Pharma team — schools, employers, funds. One of them is your warm intro.

Elena Pantaziunlockedknows Gunilla Ekström · together at INSEAD (overlapped)
×5knows the team · via INSEAD
×4knows the team · via Karolinska Institutet
×2knows the team · via Gesynta Pharma AB

Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis. Its pipeline targets inflammation- and pain-related conditions across clinical development stages.

BiotechDigital HealthFemTechMedical Devices

Founders & leadership

PS
Patric StenbergFounder
GEGunilla Ekström
Gunilla EkströminFounderGunilla Ekström has held roles spanning pharmaceutical R&D, project management, and executive leadership, including positions as a drug metabolism scientist, portfolio director overseeing analgesic compounds from discovery through clinical phase 2, CEO of a virtual pharmaceutical company, and board member at multiple life sciences firms. She has experience across the full R&D value chain from small to large pharma organizations, including investor relations and strategic financing.

Investors · 7

Amboy Street Ventures✓ verifiedVenice
Foreground Capital✓ verifiedBoston
Hadean Ventures✓ verifiedOslo
HealthCap✓ verifiedStockholm
Industrifonden✓ verifiedStockholm · $1.1M – $4.3M
XGEN Venture✓ verifiedMilan
Catalyze CapitalAmsterdam · $1.6M

Funding

SEC filings, press & company announcements

$28M disclosed across 1 of 3 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Gesynta Pharma Adds $3.9M in Series B Funding for Endometriosis Drug, Total Round Reaches $31.5M | Femtech Insiderfemtechinsider.com · Jul 2025Gesynta Pharma AB announced that it has received SEK 347 million in funding from a group of investors | MarketScreenermarketscreener.com · Jul 2025€26.5M Series B funding pushes Swedish company's endometriosis therapy to next stage - ArcticStartuparcticstartup.com · Jan 2025Sweden's Gesynta Pharma raises $28 million for novel endometriosis treatmentfuturefemhealth.com · Jan 2025🇸🇪 Gesynta Pharma raises SEK 304 million to advance novel endometriosis treatment - ArcticTodayarctictoday.com · Jan 2025Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment | Femtech Insiderfemtechinsider.com · Jan 2025

Frequently asked questions

What does Gesynta Pharma do?
Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis. Its pipeline targets inflammation- and pain-related conditions across clinical development stages.
Who founded Gesynta Pharma?
Gesynta Pharma was founded by Patric Stenberg, Gunilla Ekström.
Who are Gesynta Pharma's investors?
Gesynta Pharma's investors include Amboy Street Ventures, Foreground Capital, Hadean Ventures, HealthCap, Industrifonden, XGEN Venture, Catalyze Capital.
How much funding has Gesynta Pharma raised?
Gesynta Pharma has disclosed $28M raised across 1 of its 3 known rounds.
Where is Gesynta Pharma headquartered?
Gesynta Pharma is headquartered in Stockholm, SE.